Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (39652) 39652
Newspaper Article (1066) 1066
Book Chapter (555) 555
Newsletter (198) 198
Book / eBook (41) 41
Magazine Article (39) 39
Conference Proceeding (16) 16
Trade Publication Article (12) 12
Transcript (12) 12
Reference (9) 9
Dissertation (7) 7
Publication (7) 7
Government Document (3) 3
Web Resource (3) 3
Streaming Video (2) 2
Book Review (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (31861) 31861
science & technology (31376) 31376
life sciences & biomedicine (30442) 30442
chemotherapy (26176) 26176
female (23179) 23179
oncology (22112) 22112
middle aged (18023) 18023
cancer (17019) 17019
aged (15403) 15403
male (14639) 14639
adult (14185) 14185
antineoplastic combined chemotherapy protocols - therapeutic use (11101) 11101
treatment outcome (9934) 9934
chemotherapy, adjuvant (9051) 9051
tumors (8986) 8986
care and treatment (8185) 8185
breast cancer (8158) 8158
biological and medical sciences (8152) 8152
medical sciences (8119) 8119
antineoplastic combined chemotherapy protocols - adverse effects (7853) 7853
cancer therapies (7544) 7544
surgery (6987) 6987
breast neoplasms - drug therapy (6755) 6755
metastasis (6597) 6597
medicine & public health (6109) 6109
neoplasm staging (6041) 6041
patients (5858) 5858
research (5562) 5562
antineoplastic agents (5509) 5509
prognosis (5253) 5253
aged, 80 and over (5040) 5040
disease-free survival (4975) 4975
retrospective studies (4818) 4818
health aspects (4704) 4704
combined modality therapy (4617) 4617
analysis (4602) 4602
clinical trials (4557) 4557
pharmacology. drug treatments (4228) 4228
antineoplastic agents - therapeutic use (4156) 4156
radiotherapy (4123) 4123
risk factors (3987) 3987
radiation therapy (3753) 3753
antineoplastic agents - adverse effects (3749) 3749
survival rate (3664) 3664
survival analysis (3603) 3603
follow-up studies (3529) 3529
drug therapy (3490) 3490
breast neoplasms - pathology (3421) 3421
medical prognosis (3420) 3420
fluorouracil - administration & dosage (3406) 3406
colorectal cancer (3298) 3298
antineoplastic combined chemotherapy protocols - administration & dosage (3183) 3183
hematology, oncology and palliative medicine (2899) 2899
pharmacology & pharmacy (2821) 2821
survival (2811) 2811
quality of life (2734) 2734
drug administration schedule (2647) 2647
studies (2605) 2605
prospective studies (2604) 2604
cisplatin - administration & dosage (2591) 2591
time factors (2584) 2584
abridged index medicus (2519) 2519
toxicity (2519) 2519
adjuvant treatment (2452) 2452
oncology, experimental (2429) 2429
cancer patients (2353) 2353
adolescent (2298) 2298
animals (2283) 2283
medical research (2275) 2275
young adult (2250) 2250
patient outcomes (2232) 2232
neoadjuvant therapy (2215) 2215
immunotherapy (2164) 2164
antimitotic agents (2153) 2153
kaplan-meier estimate (2137) 2137
antineoplastic agents - administration & dosage (2084) 2084
metastases (2035) 2035
neoplasm metastasis (1995) 1995
deoxycytidine - analogs & derivatives (1976) 1976
radiotherapy, adjuvant (1915) 1915
cancer research (1905) 1905
fluorouracil - adverse effects (1905) 1905
hematology (1874) 1874
medicine (1816) 1816
usage (1815) 1815
lung cancer (1790) 1790
chemotherapy, adjuvant - adverse effects (1781) 1781
development and progression (1725) 1725
neoplasms. tumors. oncology. including cancer and carcinogens (1720) 1720
colorectal neoplasms - drug therapy (1718) 1718
research article (1689) 1689
gynecology. andrology. obstetrics (1659) 1659
mortality (1642) 1642
review (1641) 1641
dose-response relationship, drug (1638) 1638
randomized controlled trials as topic (1601) 1601
cyclophosphamide - administration & dosage (1573) 1573
multivariate analysis (1569) 1569
neoplasms - drug therapy (1545) 1545
cisplatin (1536) 1536
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (6) 6
Gerstein Science - Stacks (5) 5
Baycrest Hospital - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Holland Bloorview Kids Rehabilitation - Stacks (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Online Resources - Online (1) 1
Scarborough Hospital - Hospital Department (1) 1
Scarborough Hospital - Online (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (40535) 40535
German (455) 455
Japanese (406) 406
French (219) 219
Russian (121) 121
Chinese (80) 80
Spanish (62) 62
Portuguese (51) 51
Italian (50) 50
Hungarian (46) 46
Polish (31) 31
Dutch (15) 15
Norwegian (14) 14
Czech (10) 10
Danish (9) 9
Turkish (8) 8
Romanian (7) 7
Hebrew (6) 6
Korean (5) 5
Bulgarian (2) 2
Finnish (2) 2
Icelandic (2) 2
Lithuanian (2) 2
Ukrainian (2) 2
Arabic (1) 1
Croatian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
by Zhong, Wen-Zhao and Wang, Qun and Mao, Wei-Min and Xu, Song-Tao and Wu, Lin and Shen, Yi and Liu, Yong-Yu and Chen, Chun and Cheng, Ying and Xu, Lin and Wang, Jun and Fei, Ke and Li, Xiao-Fei and Li, Jian and Huang, Cheng and Liu, Zhi-Dong and Xu, Shun and Chen, Ke-Neng and Xu, Shi-Dong and Liu, Lun-Xu and Yu, Ping and Wang, Bu-Hai and Ma, Hai-Tao and Yan, Hong-Hong and Yang, Xue-Ning and Zhou, Qing and Wu, Yi-Long and Wu, Yi-Long and Wang, Qun and Mao, Wei-Min and Wu, Lin and Shen, Yi and Liu, Yong-Yu and Chen, Chun and Cheng, Ying and Xu, Lin and Wang, Jun and Fei, Ke and Li, Xiao-Fei and Li, Jian and Huang, Cheng and Liu, Zhi-Dong and Xu, Shun and Chen, Ke-Neng and Xu, Shi-Dong and Liu, Lun-Xu and Yu, Ping and Wang, Bu-Hai and Ma, Hai-Tao and Wang, Si-Yu and Hu, Jian and Liu, Wei and Li, Wei and Shi, Jian-Hua and ADJUVANT investigators and ADJUVANT Investigators
The lancet oncology, ISSN 1470-2045, 01/2018, Volume 19, Issue 1, pp. 139 - 148
Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Pneumonectomy | Protein Kinase Inhibitors - adverse effects | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Young Adult | Time Factors | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | China | Adult | Female | Quinazolines - administration & dosage | Chemotherapy, Adjuvant | Gefitinib | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Risk Factors | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Quinazolines - adverse effects | Cisplatin - adverse effects | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Vinorelbine | Lung cancer, Non-small cell | Care and treatment | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
by Cameron, David, Prof and Piccart-Gebhart, Martine J, PhD and Gelber, Richard D, PhD and Procter, Marion, PhD and Goldhirsch, Aron, MD and de Azambuja, Evandro, MD and Castro, Gilberto, MD and Untch, Michael, MD and Smith, Ian, MD and Gianni, Luca, MD and Baselga, Jose, MD and Al-Sakaff, Nedal, PhD and Lauer, Sabine, PhD and McFadden, Eleanor, MA and Leyland-Jones, Brian, MBBS and Bell, Richard, MBBS and Dowsett, Mitch, PhD and Jackisch, Christian, MD and Herceptin Adjuvant (HERA) Trial Study Team and Herceptin Adjuvant HERA Trial
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Trastuzumab - therapeutic use | Drug Administration Schedule | Follow-Up Studies | Biomarkers, Tumor - analysis | Humans | Middle Aged | Kaplan-Meier Estimate | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Antineoplastic Agents, Immunological - adverse effects | Breast Neoplasms - chemistry | Antineoplastic Agents, Immunological - therapeutic use | Breast Neoplasms - pathology | Chemotherapy, Adjuvant - methods | Adult | Female | Aged | Receptor, ErbB-2 - analysis | Heart Diseases - chemically induced | Antimitotic agents | Medical colleges | Analysis | Adjuvant treatment | Monoclonal antibodies | Breast cancer | Antineoplastic agents | Cancer | Heart | Medical research | Laboratories | Toxicity | Health risks | Clinical trials | Mammography | Radiation therapy | Cancer therapies | Patients | Survival | ErbB-2 protein | Incidence | Chemotherapy | Motivation | Failure analysis | Surgery | Informed consent | Heart diseases | Trastuzumab | Schedules | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
by Long, Georgina V and Hauschild, Axel and Santinami, Mario and Atkinson, Victoria and Mandalà, Mario and Chiarion-Sileni, Vanna and Larkin, James and Nyakas, Marta and Dutriaux, Caroline and Haydon, Andrew and Robert, Caroline and Mortier, Laurent and Schachter, Jacob and Schadendorf, Dirk and Lesimple, Thierry and Plummer, Ruth and Ji, Ran and Zhang, Pingkuan and Mookerjee, Bijoyesh and Legos, Jeff and Kefford, Richard and Dummer, Reinhard and Kirkwood, John M
The New England journal of medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 19, pp. 1813 - 1823
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Adjuvants, Immunologic - adverse effects | Young Adult | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Double-Blind Method | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasm Recurrence, Local | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Adolescent | Survival Analysis | Aged | Pyridones - therapeutic use | Melanoma - surgery | Mutation | Neoplasm Staging | Pyridones - adverse effects | Melanoma - mortality | Usage | Relapse | Patient outcomes | Analysis | Melanoma | Adjuvant treatment | Outcome and process assessment (Health Care) | Reports | Drug therapy | Cancer | Diseases | Medical imaging | Oncology | Metastasis | FDA approval | Kinases | Cancer therapies | Survival | Skin cancer | Metastases | Medical prognosis | Immunotherapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
by Neoptolemos, John P, Prof and Palmer, Daniel H, Prof and Ghaneh, Paula, Prof and Psarelli, Eftychia E, MSc and Valle, Juan W, MD and Halloran, Christopher M, MD and Faluyi, Olusola, MD and O'Reilly, Derek A, MD and Cunningham, David, Prof and Wadsley, Jonathan, Prof and Darby, Suzanne, MD and Meyer, Tim, Prof and Gillmore, Roopinder, MD and Anthoney, Alan, MD and Lind, Pehr, MD and Glimelius, Bengt, MD and Falk, Stephen, MD and Izbicki, Jakob R, Prof and Middleton, Gary William, MD and Cummins, Sebastian, MD and Ross, Paul J, MD and Wasan, Harpreet, MD and McDonald, Alec, MD and Crosby, Tom, MD and Ma, Yuk Ting, MD and Patel, Kinnari, MD and Sherriff, David, FRCR and Soomal, Rubin, MD and Borg, David, MD and Sothi, Sharmila, MD and Hammel, Pascal, Prof and Hackert, Thilo, MD and Jackson, Richard, PhD and Büchler, Markus W, Prof and European Study Group for Pancreatic Cancer and European Study Grp Pancreat Canc
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 389, Issue 10073, pp. 1011 - 1024
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Capecitabine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Carcinoma, Pancreatic Ductal - surgery | Antimetabolites, Antineoplastic - administration & dosage | Pancreatic Neoplasms - drug therapy | Aged, 80 and over | Adult | Carcinoma, Pancreatic Ductal - mortality | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Chemotherapy, Adjuvant | Deoxycytidine - administration & dosage | Pancreatic Neoplasms - surgery | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Pancreatic Ductal - drug therapy | Capecitabine - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Aged | Deoxycytidine - analogs & derivatives | Antimitotic agents | Cancer patients | Care and treatment | Pancreatic cancer | Clinical trials | Product development | Metastasis | Comparative analysis | Antineoplastic agents | Studies | Antigens | Chemotherapy | Acids | Pragmatism | Pharmaceutical industry | Cancer therapies | Abdomen | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Surgery | Kirurgi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
by Francis, Prudence A and Regan, Meredith M and Fleming, Gini F and Láng, István and Ciruelos, Eva and Bellet, Meritxell and Bonnefoi, Hervé R and Climent, Miguel A and Da Prada, Gian Antonio and Burstein, Harold J and Martino, Silvana and Davidson, Nancy E and Geyer, Charles E and Walley, Barbara A and Coleman, Robert and Kerbrat, Pierre and Buchholz, Stefan and Ingle, James N and Winer, Eric P and Rabaglio-Poretti, Manuela and Maibach, Rudolf and Ruepp, Barbara and Giobbie-Hurder, Anita and Price, Karen N and Colleoni, Marco and Viale, Giuseppe and Coates, Alan S and Goldhirsch, Aron and Gelber, Richard D and Int Breast Canc Study Grp and SOFT Investigators and International Breast Cancer Study Group
The New England journal of medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 5, pp. 436 - 446
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Breast Neoplasms - surgery | Premenopause | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Mastectomy | Adult | Female | Androstadienes - therapeutic use | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Chemotherapy | Womens health | Invasiveness | Estrogens | Population studies | Breast cancer | Reproductive system | Tamoxifen | Drug therapy | Survival | Patients | Statistical analysis | Endocrine therapy | Radiation therapy | Cancer therapies | Survival analysis | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
by Pagani, Olivia and Regan, Meredith M and Walley, Barbara A and Fleming, Gini F and Colleoni, Marco and Láng, István and Gomez, Henry L and Tondini, Carlo and Burstein, Harold J and Perez, Edith A and Ciruelos, Eva and Stearns, Vered and Bonnefoi, Hervé R and Martino, Silvana and Geyer, Charles E and Pinotti, Graziella and Puglisi, Fabio and Crivellari, Diana and Ruhstaller, Thomas and Winer, Eric P and Rabaglio-Poretti, Manuela and Maibach, Rudolf and Ruepp, Barbara and Giobbie-Hurder, Anita and Price, Karen N and Bernhard, Jürg and Luo, Weixiu and Ribi, Karin and Viale, Giuseppe and Coates, Alan S and Gelber, Richard D and Goldhirsch, Aron and Francis, Prudence A and TEXT SOFT Investigators Int Breast and International Breast Cancer Study Group and TEXT and SOFT Investigators
The New England journal of medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 2, pp. 107 - 118
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | General aspects | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Estradiol - blood | Breast Neoplasms - surgery | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | Aromatase Inhibitors - therapeutic use | Osteoporosis - chemically induced | Premenopause | Kaplan-Meier Estimate | Triptorelin Pamoate - adverse effects | Triptorelin Pamoate - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tamoxifen - therapeutic use | Quality of Life | Androstadienes - therapeutic use | Tamoxifen - adverse effects | Androstadienes - adverse effects | Care and treatment | Breast cancer | Research | Ovariectomy | Invasiveness | Estrogens | Radiation | Clinical trials | Data processing | Pituitary (anterior) | Gonadotropins | Tamoxifen | Survival | Patients | Clinical outcomes | Post-menopause | Chemotherapy | Aromatase | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial
by Piccart-Gebhart, Martine and Holmes, Eileen and Baselga, Jośe and De Azambuja, Evandro and Dueck, Amylou C and Viale, Giuseppe and Zujewski, Jo Anne and Goldhirsch, Aron and Armour, Alison and Pritchard, Kathleen I and McCullough, Ann E and Dolci, Stella and McFadden, Eleanor and Holmes, Andrew P and Tonghua, Liu and Eidtmann, Holger and Dinh, Phuong and Di Cosimo, Serena and Harbeck, Nadia and Tjulandin, Sergei and Im, Young-Hyuck and Huang, Chiun-Sheng and Díeras, Veronique and Hillman, David W and Wolff, Antonio C and Jackisch, Christian and Lang, Istvan and Untch, Michael and Smith, Ian and Boyle, Frances and Xu, Binghe and Gomez, Henry and Suter, Thomas and Gelber, Richard D and Perez, Edith A
Journal of clinical oncology, ISSN 0732-183X, 04/2016, Volume 34, Issue 10, pp. 1034 - 1042
Life Sciences & Biomedicine | Oncology | Science & Technology | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Agents - administration & dosage | Patient Selection | Breast Neoplasms - chemistry | Antineoplastic Agents - adverse effects | Adult | Female | Quinazolines - administration & dosage | Chemotherapy, Adjuvant | Lapatinib | Drug Administration Schedule | Biomarkers, Tumor - analysis | Kaplan-Meier Estimate | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quinazolines - adverse effects | Aged | Receptor, ErbB-2 - analysis | Neoplasm Staging | Index Medicus | Bc6 | Rc | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
by Bruix, Jordi, Prof and Takayama, Tadatoshi, Prof and Mazzaferro, Vincenzo, Prof and Chau, Gar-Yang, Prof and Yang, Jiamei, Prof and Kudo, Masatoshi, Prof and Cai, Jianqiang, Prof and Poon, Ronnie T, Prof and Han, Kwang-Hyub, Prof and Tak, Won Young, Prof and Lee, Han Chu, Prof and Song, Tianqiang, MD and Roayaie, Sasan, MD and Bolondi, Luigi, Prof and Lee, Kwan Sik, Prof and Makuuchi, Masatoshi, Prof and Souza, Fabricio, MD and Berre, Marie-Aude Le, MSc and Meinhardt, Gerold, MD and Llovet, Josep M, Prof and STORM investigators and STORM Investigators
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1344 - 1354
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Catheter Ablation - mortality | South America | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Hepatectomy - mortality | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | North America | Young Adult | Carcinoma, Hepatocellular - drug therapy | Time Factors | Aged, 80 and over | Liver Neoplasms - pathology | Catheter Ablation - adverse effects | Chemotherapy, Adjuvant | Europe | Risk Factors | Niacinamide - adverse effects | Niacinamide - therapeutic use | Disease Progression | New Zealand | Protein Kinase Inhibitors - administration & dosage | Intention to Treat Analysis | Niacinamide - analogs & derivatives | Liver Neoplasms - mortality | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adult | Female | Double-Blind Method | Hepatectomy - adverse effects | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Neoplasm Recurrence, Local | Phenylurea Compounds - therapeutic use | Carcinoma, Hepatocellular - surgery | Liver Neoplasms - surgery | Treatment Outcome | Niacinamide - administration & dosage | Disease-Free Survival | Phenylurea Compounds - administration & dosage | Asia | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Aged | Australia | Antimitotic agents | Liver cancer | Medical colleges | Surgery | Liver | Clinical trials | Hepatoma | Antineoplastic agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights